Seeking Insights into Resistance to Two Antibiotics

摘要

A longstanding riddle underlying the resistance of particular bacterial pathogens to polymyxin B-itself a vintage antimicrobial peptide-yielded to analysis revealing a newly recognized self-modification process in gram-negative bacteria, according to Stephen Trent of the University of Texas (UT) at Austin and his collaborators. Meanwhile, a clinical trial evaluating a new boron-containing antibacterial agent, designated GSK2251052 (also called GSK052 or AN3365), was suspended early this year when patients with urinary tract infections being treated developed resistance to this experimental drug, according to ClinicalTrials.gov，which is maintained by the National Institutes of Health.